Comprehensive Study Notes: Cellular Injury, Pathophysiology, and Medical Genetics

Cellular Injury: Etiology and Mechanisms

• Cellular injury occurs when environmental stresses exceed the cell's ability to adapt, leading to structural and functional alterations.

• Structural organization of living organisms proceeds hierarchically from fundamental chemical units to complex multicellular systems:

  • Atom $\rightarrow$ Molecule $\rightarrow$ Macromolecule $\rightarrow$ Cell $\rightarrow$ Tissue $\rightarrow$ Organ $\rightarrow$ Organ System $\rightarrow$ Organism.

Etiological Categories of Cell Injury

• Deficiency: A lack of any substance necessary to maintain cellular life, metabolism, signaling, or structural integrity.

  • Primary Nutrient Deficiency: Direct failure to ingest required nutrients or essential substances.

  • Secondary Nutrient Deficiency: Adequate ingestion occurs, but the cell cannot absorb, transport, or utilize the substance due to underlying conditions.

  • Example: Intestinal tapeworm infection "robbing" the host organism of absorbed nutrients.

  • Example: Intestinal malabsorption syndromes preventing nutrient uptake.

  • Genetic Disease: Inherited defects that cause impaired metabolite regulation or impaired metabolite synthesis.

  • Infection: Infectious agents consuming or depleting cellular nutrients needed by host tissues.

• Intoxication: Cellular poisoning caused by the presence of toxic substances that interfere directly with cellular metabolism or structural integrity.

  • Exogenous Origin:

  • Biological toxins: Toxins produced by living organisms (e.g., Clostridium botulinum neurotoxin).

  • Nonbiological toxins: Chemical poisons, heavy metals, and toxic environmental fumes.

  • Endogenous Origin:

  • Internal accumulation of toxic metabolic products.

  • Genetic defects in enzymes leading to:

    • Defective enzyme activity $\rightarrow$ Accumulation of a normal metabolite to toxic thresholds.

    • Defective enzyme activity $\rightarrow$ Activation of an alternate metabolic pathway producing toxic compounds.

    • Direct endogenous toxin production.

  • Impaired circulation leading to accumulation of metabolic waste products in tissues.

• Ethanol Intoxication Pathway:

  • Ethanol metabolism occurs across two cellular compartments:

    • Cytoplasm: Ethanol is converted to Acetaldehyde by the enzyme Alcohol Dehydrogenase (ADH).

    • Mitochondria: Acetaldehyde is converted to Acetic Acid by the enzyme Aldehyde Dehydrogenase (ALDH).

  • Accumulation of acetaldehyde due to enzymatic imbalance or excessive ethanol consumption causes direct toxic damage and heavily influences hangover symptoms.

• Trauma: Physical injury or direct disruption of cellular mechanical and structural integrity.

  • Hypothermia: Cold temperatures cause ice crystal formation that physically ruptures cell membranes.

  • Hyperthermia / Burns: Thermal energy denatures critical structural proteins and enzymes, killing cells.

  • Radiation: Solar radiation and ionizing radiation break chemical bonds, inducing lethal double-strand DNA damage.

  • Mechanical Pressure: Barotrauma or physical compression destroying cellular structure.

  • Electric Current: Thermal damage and membrane disruption from electrical discharge.

  • Foreign Microorganisms: Viral infection inducing cell lysis.

  • Immune Action: Cytotoxic T cells punching pore-forming holes (perforins) in cell membranes or complement-mediated membrane attack complex (MAC) insertion.

Cellular Responses to Injury: Reversible vs. Irreversible

• Cellular responses to injury exist on a continuum between reversible adaptation and irreversible cell death.

• Structural and functional changes go hand in hand; functional derangements invariably reflect underlying organellar or molecular structural changes.

Irreversible Cellular Response: Cell Death

• Apoptosis (Programmed Cell Death):

  • A systematic, energy-dependent process of deliberate cellular self-destruction.

  • Frequently utilized by physiological systems to control cell populations, eliminate damaged cells, or sculpt tissue during development.

  • Characterized by cellular recycling: dead cell components are systematically packaged and engulfed by neighboring cells or specialized macrophages without triggering an inflammatory response.

  • Historical Origin and Terminology:

  • Term introduced in a landmark publication by J. F. R. Kerr, A. H. Wyllie, and A. R. Currie in the British Journal of Cancer (April 1972, Vol. 26, p. 239) from the Department of Pathology at the University of Aberdeen.

  • Proposed by Professor James Cormack of the Department of Greek at the University of Aberdeen.

  • Derived from the Greek word $\alpha\pi\acute{o}\pi\tau\omega\sigma\iota\sigma$, used to describe the "dropping off" or "falling off" of petals from flowers or leaves from trees.

  • Pronunciation rules specify stress on the penultimate syllable, with the second half pronounced like "ptosis" (with a silent 'p'), sharing the root meaning "to fall" (as in eyelid ptosis).

  • Morphological Sequence of Apoptosis:

  • Parenchymal cell separation from adjacent cells.

  • Cytoplasmic condensation and chromatin condensation.

  • Cell fragmentation into membrane-bound apoptotic bodies.

  • Phagocytosis of apoptotic bodies by histiocytes or macrophages.

  • Lysosomal digestion and autolysis within the histiocyte/macrophage.

  • Formation of an inert residual body.

• Necrotic Changes (Unregulated Cell Breakdown):

  • Extreme, uncompensated structural changes resulting in organelle breakdown and loss of plasma membrane integrity.

  • Nuclear Morphological Stages of Necrosis:

  • Karyolysis: Nuclear chromatin fragments and degrades, causing the nucleus to "melt away" or lose its staining intensity.

  • Pyknosis: Nuclear shrinkage and extreme condensation into a dense, dark, featureless mass.

  • Karyorrhexis: Fragmentation of the pyknotic cell nucleus into small, dense chromatin blocks.

Reversible Cellular Responses

• Reversible functional and structural adaptations allow cells to withstand sublethal stress and regain homeostasis when the injurious stimulus is removed.

• Functional Adaptive Responses:

  • Alternate Metabolism:

  • Shifting metabolic pathways to cope with microenvironmental stress.

  • Example: Switching between oxidative phosphorylation and anaerobic glycolysis under hypoxic conditions or in transformed cancer cells.

  • Alteration of Cell Size and Number:

  • Hypertrophy: Increase in individual cell size, expanding tissue volume without changing cell count (e.g., in response to increased mechanical workload or swelling).

  • Hyperplasia: Increase in total cell number through mitotic division.

  • Atrophy: Decrease in cell size and functional capacity (wasting away) in response to pressure, disuse, nutrient deprivation, or diminished hormonal stimulation.

• Cell Stress Proteins (Heat Shock Proteins / HSPs):

  • Thermal injury, fever, or cellular stress induces protein denaturation.

  • Injury triggers expression of cell stress proteins (molecular chaperones).

  • Stress proteins bind to denatured or misfolded proteins to:

    • Stabilize protein tertiary structure.

    • Restore normal functional protein conformation.

    • Facilitate targeted enzymatic destruction of irreparable proteins, limiting cellular damage.

• Organelle Alterations:

  • Mitochondria: Dynamic shifts in mitochondrial morphology (fusion, fission, swelling).

  • Lysosomes: Induction of autophagy to remove damaged organelles, resulting in autophagocytic vacuoles and accumulation of indigestible lipofuscin granules ("wear-and-tear" pigment).

  • Lipid Accumulation: Reversible accumulation of neutral fat droplets within parenchymal cells (e.g., hepatic steatosis in Nonalcoholic Fatty Liver Disease [NAFLD] and Nonalcoholic Steatohepatitis [NASH]).

  • Structural Reversible Changes:

• Plasma Membrane Alterations:

  • Plasma Membrane Blebbing: The first visible morphological indicator of membrane damage, characterized by localized bubble-like outpouchings of the plasma membrane.

• Structural modifications to membrane-bound organelles, including altered processing or cleavage of structural proteins (such as Tau protein alterations into Tau441 and Tau421 forms).

Molecular Pathophysiology of Specific Genetic Disorders

Muscular Dystrophy

• Etymology: Derived from Greek dis- (bad or faulty) and -trophy (nourishment/growth), producing a clinical appearance of progressive muscle wasting.

• Key Anatomical Definitions:

  • Myofibril: Contractile bundle composed of interdigitated actin (F-actin) and myosin filaments.

  • Sarcolemma: The plasma membrane surrounding a muscle fiber cell.

• Genetic Basis:

  • Caused by genetic mutations in (or related to) the dystrophin gene.

  • The dystrophin gene is exceptionally large and located on the X chromosome.

  • Mode of Inheritance: X-linked recessive (predominantly affecting males; females are usually asymptomatic carriers).

• Major Clinical Forms:

  • Duchenne Muscular Dystrophy (DMD): Most common and most severe form. Frameshift or severe mutations result in virtually zero functional dystrophin protein.

  • Becker Muscular Dystrophy (BMD): Less common and less severe. In-frame mutations result in protein misfolding, but retain partial dystrophin function.

• Molecular Mechanics & Pathophysiological Sequence:

  • Normal Function: Dystrophin serves as a mechanical anchor, binding intracellular F-actin filaments to the dystrophin-glycoprotein complex (which includes sarcoglycan and dystroglycan complexes), thereby coupling the internal cytoskeleton to the sarcolemma and Extracellular Matrix (ECM).

  • Absence/Defect of Dystrophin: Filaments disconnect from the sarcolemma and ECM.

  • Repetitive muscle contraction exerts unbuffered shear stress on the unanchored membrane, tearing the sarcolemma.

  • Membrane rupture permits Creatine Kinase (CK) to escape from the muscle cell into the bloodstream (elevated serum CK is a key diagnostic biomarker).

  • Membrane rupture causes an uncontrolled influx of extracellular Calcium ($Ca^{2+}$) down its concentration gradient into the muscle cell cytoplasm.

  • Intracellular $Ca^{2+}$ overload persistently activates destructive intracellular proteases and enzymes, degrading structural proteins and destroying muscle fibers, leading to replacement by fibrous and fatty tissue.

Cystic Fibrosis

• Genetic Basis: Autosomal recessive loss-of-function mutations in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene located on Chromosome 7.

• Normal Protein Function:

  • CFTR is a cAMP-dependent chloride ($Cl^-$) and bicarbonate ($HCO_3^-$) ion channel expressed on the apical membrane of exocrine glands and epithelial tissues (lungs, respiratory tract, sweat glands, pancreas, intestines, liver, and sinuses).

• Most Common Mutation:

  • $\Delta F508$: A deletion of three nucleotides encoding phenylalanine at position 508.

  • This deletion causes misfolding and defective ATP binding, preventing the channel from opening and leading to a complete lack of functional protein at the cell surface.

• Tissue-Specific Pathophysiology:

  • Epithelial and Mucosal Surfaces (Lungs, Pancreas, Intestines, Sinuses):

  • Normal Physiology: CFTR secretes $Cl^-$ and $HCO_3^-$ out of epithelial cells into the lumen, drawing $Na^+$ and $H_2O$ osmotically to maintain thin, fluid mucus.

  • Mutant CFTR Physiology: Impaired secretion of $Cl^-$ and $HCO_3^-$ reduces luminal water content.

  • Secretions become excessively thick, sticky, and dehydrated, clogging exocrine ducts and respiratory passages.

  • Luminal ductal obstruction causes tissue destruction, cyst formation, and progressive scarring ("cyst phenotype + fibrosis"), leading to recurrent pulmonary infections, exocrine pancreatic insufficiency, and male infertility.

  • Absence of luminal $HCO_3^-$ prevents neutralization of stomach acid in the duodenum.

  • Sweat Glands:

  • Normal Physiology: CFTR reabsorbs $Cl^-$ (and $Na^+$ passively follows) from primary sweat as it flows through the sweat gland duct, producing hypotonic sweat.

  • Mutant CFTR Physiology: Epithelial cells fail to reabsorb $Cl^-$ and $Na^+$, producing highly concentrated, salty sweat.

  • Manifests clinically as salty skin, causing a high risk of hyponatremic dehydration; measured clinically via the sweat chloride diagnostic test.

Introduction to Human Genetics and Clinical Genomics

Consumer Genetics & High-Profile Susceptibility Alleles

• The proliferation of direct-to-consumer (DTC) genetic testing (e.g., 23andMe, AncestryDNA) and rapid decreases in whole-genome sequencing costs (driven by companies like Illumina, achieving the $\$600$ human genome) have introduced vast genetic risk data directly to patients, raising significant challenges regarding clinical management and interpretation.

• BRCA1/BRCA2 & Hereditary Breast/Ovarian Cancer ("The Angelina Jolie Effect"):

  • BRCA1 and BRCA2 encode critical proteins required for homologous recombination repair of double-strand DNA breaks.

  • A pathogenic BRCA1 mutation elevates lifetime breast cancer risk from a baseline population risk of $\approx 13\%$ up to approximately $60\%$

  • Clinical Implications: Bilateral prophylactic mastectomies (Contralateral Risk-Reducing Mastectomy [CRRM]) are frequently pursued by mutation carriers, despite clinical data demonstrating that bilateral mastectomy does not always improve overall survival compared to breast-conserving lumpectomy combined with local radiation.

  • The "Angelina Jolie Effect": High-profile public disclosure of BRCA1 carrier status in 2013 triggered an immediate and dramatic spike in CRRM procedures among diagnosed high-risk patients (rising from a $\approx 24\%$ baseline to near $70\%$ in 2013).

• APOE $\epsilon4$ & Alzheimer's Disease Risk ("Chris Hemsworth Case"):

  • APOE encodes Apolipoprotein E, involved in lipid transport and neurobiology.

  • The APOE $\epsilon4$ allele is the strongest genetic risk factor for sporadic late-onset Alzheimer's Disease (AD).

  • Carrying two copies ($\epsilon4/\epsilon4$ homozygote) increases lifetime risk of Alzheimer's disease by $8\text{--}12\times$, causing earlier disease onset and greater clinical severity.

  • Pathophysiological Mechanisms of APOE4:

  • Loss of Normal Function:

    • Decreased Long-Term Potentiation (LTP) and synaptic plasticity.

    • Decreased Amyloid-$\beta$ ($A\beta$) clearance.

    • Decreased mitochondrial energy metabolism.

    • Decreased cellular autophagy.

    • Decreased conversion of glutamine to glutamate.

    • Disrupted pErk $\rightarrow$ pTau regulation.

    • Impaired cholesterol transport causing mitochondrial hyperactivity.

  • Gain of Toxic Function:

    • Increased formation of toxic Amyloid Plaques.

    • Increased insulin resistance (mediated via pAkt inhibition $\rightarrow$ decreased GLUT4 expression $\rightarrow$ reduced neuronal glucose uptake).

    • Increased hyperphosphorylated Tau (pTau) aggregation into neurofibrillary tangles.

    • Microglial synaptic phagocytosis $\rightarrow$ accumulation of senescent neurons.

    • Increased proinflammatory microglial activation.

    • ApoER2 receptor uptake $\rightarrow$ decreased LTP.

    • Aggressive ApoE/$A\beta$ binding $\rightarrow$ increased overall $A\beta$ burden.

    • Neuronal uptake of $A\beta \rightarrow$ upregulation of Amyloid Precursor Protein (APP) $\rightarrow$ increased $A\beta$ synthesis.

    • mTOR activation $\rightarrow$ suppressed autophagy $\rightarrow$ accumulation of pTau and $A\beta$

  • Experimental Therapeutics: Gene therapy (converting genotype to APOE3), PPAR agonists, Anti-ApoE4 monoclonal antibodies, small molecule inhibitors, and LXR/RXR nuclear receptor agonists.

Prenatal Genetic Screening

• Non-Invasive Prenatal Testing (NIPT):

  • Screen performed by analyzing Cell-free Fetal DNA (cfDNA) circulating in the maternal bloodstream.

  • Recommended by ACOG (American College of Obstetricians and Gynecologists) guidelines for all pregnancies, regardless of baseline maternal risk.

  • Market Growth: US market valued at $\$788\text{ MN}$ in 2021, projected to reach $\$2{,}557\text{ MN}$ by 2028 (Compound Annual Growth Rate [CAGR] of $13.9\%$ from 2022 to 2030).

  • FDA Warning: The FDA issued a formal news release warning clinicians and patients about the screening nature of NIPT, highlighting that misinterpretation of screening results (which carry false-positive risks) can lead to irreversible, improper medical decisions (such as elective pregnancy termination without confirmatory invasive diagnostic testing like amniocentesis or chorionic villus sampling).

Fundamental Concepts in Genetics

• Primary Cause of Genetic Disease: A change in the nucleotide sequence or cellular content of DNA that ultimately deranges gene expression (most commonly a single gene product; less frequently a multigene locus or whole chromosome).

• Karyotype: A visual display of an individual's complete chromosome complement, used to analyze chromosomal numerical or structural abnormalities.

• Genotype vs. Phenotype:

  • Genotype: The specific underlying genetic constitution of an organism.

  • Phenotype: The observable outward physical, biochemical, or physiological manifestation of the genotype.

  • Genotype does not strictly dictate phenotype due to modifying factors.

• Variable Expressivity: The degree or severity to which a given genotype exhibits its phenotypic expression among different affected individuals. Persons carrying the exact same disease-causing mutation can display striking clinical variation.

• Penetrance: The proportion of individuals carrying a disease-causing mutation who express the clinical phenotype.

  • Complete Penetrance: $100\%$ of individuals with the mutation display the phenotype.

  • Reduced / Incomplete Penetrance: Less than $100\%$ of individuals with the mutant genotype display clinical signs of the disease (some remain completely asymptomatic).

Pedigree Construction and Rules

• A pedigree is a standardized graphical representation of a family lineage, depicting medical history, phenotypic status, and biological relationships.

• Standard Symbols and Rules:

  • Generations are designated by Roman Numerals ($\text{I}, \text{II}, \text{III}$, etc.) listed vertically from top to bottom.

  • Individuals within a generation are designated by Arabic Numerals ($1, 2, 3$, etc.) listed left to right.

  • Siblings are placed in birth order from left to right (oldest sibling on the far left).

  • Males are represented by Squares; Females are represented by Circles.

  • Affected individuals are designated by fully filled/shaded shapes.

  • Deceased individuals are indicated by a diagonal slash/strikethrough.

  • Proband: The affected individual who first brings the family to medical attention, designated by a specific arrow.

Practice Pedigree Construction Case Study

• Clinical Prompt: Sarah, a 28-year-old female, seeks genetic counseling because her 65-year-old paternal uncle was newly diagnosed with Huntington's disease. Sarah has two younger brothers, both of whom have one daughter each. Sarah has no children. Her father has one sister. Her mother is an only child. All four of Sarah's grandparents are deceased.

• Pedigree Structure Breakdown:

  • Generation I (Grandparents):

  • Paternal Grandparents: I-1 (Male, deceased/slashed) married to I-2 (Female, deceased/slashed).

  • Maternal Grandparents: I-3 (Male, deceased/slashed) married to I-4 (Female, deceased/slashed).

  • Generation II (Parents, Aunts, Uncles):

  • Paternal Siblings (Offspring of I-1 & I-2): II-2 (Paternal Uncle, 65yo male, affected/shaded), II-3 (Sarah's Father, male), II-1 or II-4 (Paternal Aunt, female).

  • II-3 (Sarah's Father) married II-4 (Sarah's Mother, only child of I-3 & I-4).

  • Generation III (Sarah and Siblings):

  • Sarah: III-1 or III-2 (28yo female, Proband, designated with an arrow).

  • Younger Brothers: III-2 and III-3 (or III-3 and III-4, males, unaffected).

  • Generation IV (Niece Generation):

  • IV-1: Daughter of first brother.

  • IV-2: Daughter of second brother.

Inborn Errors of Metabolism: Phenylketonuria (PKU)

Etiology and Inherited Defect

• Incidence: Occurs in approximately $1:10{,}000$ live births.

• Inheritance Pattern: Autosomal recessive.

• Enzymatic Defect: Caused by loss-of-function mutations in the gene encoding Phenylalanine Hydroxylase (PAH), rendering the enzyme inactive or deficient.

• Normal Metabolic Pathway:

  • Phenylalanine Hydroxylase (PAH) converts the essential dietary amino acid Phenylalanine (Phe) into Tyrosine (Tyr) in the liver.

  • Tyrosine is a critical precursor for protein synthesis, melanin pigment, catecholamines (dopamine, noradrenaline, adrenaline), ketone bodies, and gluconeogenesis.

Pathophysiology of PKU

• Disease manifestations stem from a dual mechanism: Substrate Accumulation (Hyperphenylalaninemia) combined with End-Product Deficiency (Tyrosine Deficiency).

• Hyperphenylalaninemia & Blood-Brain Barrier (BBB) Transport Competition:

  • Inactivity of PAH causes severe accumulation of Phenylalanine in the bloodstream.

  • Phenylalanine, Tryptophan (Trp), and Tyrosine (Tyr) share the same transporter—the LAT1 (Large Neutral Amino Acid Transporter 1)—for transport across the Blood-Brain Barrier into the central nervous system.

  • Extremely elevated blood Phe levels saturate the LAT1 transporter, competitively inhibiting LAT1-mediated transport of Tryptophan and Tyrosine into the brain.

  • Neurotransmitter Depletion:

  • Reduced cerebral Tryptophan uptake $\rightarrow$ Severe depletion of brain Serotonin levels.

  • Reduced cerebral Tyrosine uptake $\rightarrow$ Severe depletion of brain Dopamine, Noradrenaline, and Adrenaline levels.

  • Disrupted catecholamine feedback causes downstream elevation of blood prolactin ($\uparrow$ Prl).

  • High cerebral Phe causes direct neurotoxicity, disrupting cellular energy production, gluconeogenesis, and protein synthesis in neurons.

Clinical Phenotype of PKU

• Severe intellectual disability and cognitive impairment.

• Growth restriction and microcephaly.

• Recurrent seizures.

• Eczema and severe skin dermatoses.

• Hypopigmentation (fair hair, light skin, blue eyes) due to lack of Tyrosine for melanin synthesis.

Management and Advanced Therapies

• Dietary Restriction: Current primary standard of care requires immediate post-natal lifetime restriction of dietary Phenylalanine.

  • Prohibited / Heavily Restricted Foods (High Protein): Milk, eggs, cheese, nuts, soy products (tofu, tempeh, soy milk), beans, peas, poultry, beef, pork, organ meats, and fish.

  • Restricted Foods: Potatoes, grains, and high-protein vegetables are strictly calculated and limited.

• Gene Editing: Homology Medicines initiated the world's first human gene editing clinical trial targeted at correcting the PAH locus to restore endogenous enzyme synthesis.

Comprehensive Overview of Major Inherited Disorders